HTLV-1/2 Lab Interpretation 2026 Update Patient-Friendly A reactive HTLV screening result does not establish infection or mean cancer. Confirmatory antibody testing—and sometimes proviral DNA PCR—clarifies whether infection is present and which virus type needs counseling. 📖 ~12 minutes 📅 October 9, 2026 📝 Published: October 9, 2026 🩺 Medically Reviewed: October 9, 2026 ✅ Evidence-Based […]
Infectious Disease Lab Interpretation 2026 Update Patient-Friendly A positive antibody result can reflect an old immune response rather than living bacteria. Exposure timing, symptoms and the exact laboratory method determine what should happen next. 📖 ~12 minutes 📅 October 9, 2026 📝 Published: October 9, 2026 🩺 Medically Reviewed: October 9, 2026 ✅ Evidence-Based This […]
Medication Monitoring Lab Interpretation 2026 Update Patient-Friendly A total phenytoin concentration measures bound and unbound drug together. When protein binding changes, the number on the report may no longer reflect the concentration affecting the brain. 📖 ~12 minutes 📅 October 9, 2026 📝 Published: October 9, 2026 🩺 Medically Reviewed: October 9, 2026 ✅ Evidence-Based […]
Anesthesia Safety Lab Interpretation 2026 Update Patient-Friendly A low dibucaine number can suggest an inherited enzyme variant that prolongs paralysis after succinylcholine or mivacurium. Tell your anesthesiologist before treatment; the result measures enzyme behavior, not how much enzyme activity you have. 📖 ~12 minutes 📅 October 9, 2026 📝 Published: October 9, 2026 🩺 Medically […]
Cystic Fibrosis Lab Interpretation 2026 Update Patient-Friendly A borderline sweat chloride result of 30–59 mmol/L does not confirm cystic fibrosis. It means the result needs follow-up: usually repeat testing at an experienced center, review of symptoms and newborn screening, and sometimes CFTR genetic or functional evaluation. 📖 ~12 minutes 📅 October 8, 2026 📝 Published: […]
Medication Safety Lab Interpretation 2026 Update Patient-Friendly For heart failure, digoxin levels are usually targeted around 0.5–0.9 ng/mL; for atrial fibrillation, current US guidance recommends below 1.2 ng/mL when levels are measured. Samples generally need at least 6–8 hours after a dose. Toxicity can occur within the laboratory interval, especially with kidney impairment, low potassium […]
Medication Monitoring Lab Interpretation 2026 Update Patient-Friendly For epilepsy, many laboratories use 3–15 mg/L as a reference interval; bipolar disorder has no established concentration target. Interpret the result alongside dose timing, symptoms, and interacting medicines—not as an instruction to change your dose. 📖 ~12 minutes 📅 October 8, 2026 📝 Published: October 8, 2026 🩺 […]
Autoimmune Diabetes Lab Interpretation 2026 Update Patient-Friendly A positive result can support pancreatic autoimmunity, help investigate a specific neurologic syndrome, or be incidental. The deciding clues are the clinical picture, laboratory method, units, and supporting tests—not the positive flag alone. 📖 ~12 minutes 📅 October 8, 2026 📝 Published: October 8, 2026 🩺 Medically Reviewed: […]
Hematology Lab Interpretation 2026 Update Patient-Friendly ADAMTS13 activity below 10% strongly supports TTP when low platelets and red-cell destruction occur together, but an isolated result does not prove an acute episode. Suspected TTP needs emergency assessment and treatment decisions without waiting for the laboratory result. 📖 ~12 minutes 📅 October 8, 2026 📝 Published: October […]
Chemotherapy Safety Lab Interpretation 2026 Update Patient-Friendly DPYD testing identifies inherited variants that can make fluorouracil or capecitabine dangerously difficult to clear. Results help clinicians choose treatment and starting doses, but a negative genetic screen does not guarantee safety. 📖 ~12 minutes 📅 October 7, 2026 📝 Published: October 7, 2026 🩺 Medically Reviewed: October […]